Hospital
Logan General Hospital LLC
Logan General Hospital LLC was paid $43.43M by Medicaid between Jan 2018 and Dec 2024, across 307 billing codes. Its largest line is 99285, emergency room visit (most serious) — 12% of everything it billed.
33Billing provider infoLOGAN GENERAL HOSPITAL LLC
LOGAN, WV 25601
LOGAN, WV 25601
33aNPI1750332565assigned 05/15/2006
33bProvider typeRural Acute Care Hospital
28Total paid$43.43M
24GClaims829,016
24DCodes billed307
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TRAYLOR, JOHNETTA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 194,112 | $14.30M | |
| 2019 | 113,090 | $8.98M | |
| 2020 | 154,568 | $10.10M | |
| 2021 | 132,304 | $3.73M | |
| 2022 | 76,705 | $2.24M | |
| 2023 | 93,297 | $2.56M | |
| 2024incomplete | 64,940 | $1.53M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 14,125 | 11,807 | $5.36M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 33,903 | 29,220 | $5.00M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 6.2% | 11,729 | 10,517 | $2.71M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.0% | 19,046 | 17,638 | $1.76M |
| G0378 | Hospital observation service, per hour | 3.4% | 4,660 | 2,561 | $1.50M |
| 80053 | Comprehensive metabolic panel | 3.0% | 65,159 | 52,246 | $1.30M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 67,097 | 51,815 | $1.20M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 5,014 | 3,323 | $958K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 4,660 | 4,083 | $832K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.5% | 1,515 | 1,344 | $635K |
| J2704 | Injection, propofol, 10 mg | 1.2% | 7,331 | 6,539 | $542K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 46,658 | 39,119 | $521K |
295 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 6,558 | $471K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 4,777 | $459K |
| 71045 | Radiologic examination, chest; single view | 1.0% | 17,460 | $437K |
| 84484 | <1% | 17,556 | $434K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,747 | $430K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,934 | $408K |
| 83605 | <1% | 21,628 | $399K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,224 | $397K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,509 | $397K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,681 | $396K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,257 | $391K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,584 | $375K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,143 | $375K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 6,428 | $352K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,504 | $323K |
| 81000 | <1% | 27,883 | $323K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,324 | $308K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,877 | $289K |
| 83874 | <1% | 4,983 | $281K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,653 | $276K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,874 | $276K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,577 | $274K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,471 | $270K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,742 | $266K |
| 82553 | <1% | 4,797 | $264K | |
| 87040 | <1% | 7,734 | $263K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,203 | $258K |
| 83880 | <1% | 5,899 | $256K | |
| 82550 | <1% | 5,321 | $253K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,528 | $251K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,572 | $241K |
| 85610 | <1% | 10,301 | $235K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,976 | $228K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,826 | $228K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,822 | $226K |
| 85730 | <1% | 8,864 | $220K | |
| 83735 | <1% | 8,189 | $212K | |
| 93017 | <1% | 1,681 | $204K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,845 | $191K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,692 | $188K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,840 | $184K |
| 80061 | Lipid panel | <1% | 9,797 | $182K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,258 | $182K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,110 | $179K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,229 | $176K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,759 | $166K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,688 | $166K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,175 | $165K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,979 | $158K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,295 | $158K |
| 83690 | <1% | 7,873 | $156K | |
| 82803 | <1% | 3,121 | $156K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,230 | $153K |
| 82948 | <1% | 6,392 | $148K | |
| 71250 | <1% | 2,449 | $144K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,395 | $132K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 646 | $127K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 496 | $118K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,508 | $117K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,274 | $117K |
| 96376 | <1% | 899 | $112K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,348 | $110K |
| 81025 | <1% | 3,194 | $106K | |
| 80074 | <1% | 1,156 | $103K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,093 | $102K |
| 84439 | <1% | 5,186 | $101K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 4,413 | $100K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,300 | $98K |
| 84703 | <1% | 3,894 | $97K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,480 | $95K |
| 36600 | <1% | 2,861 | $91K | |
| 87070 | <1% | 4,061 | $90K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 561 | $90K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 729 | $86K |
| 87486 | <1% | 728 | $86K | |
| 87581 | <1% | 728 | $86K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,346 | $85K |
| 73562 | <1% | 2,334 | $85K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,014 | $83K |
| 73630 | <1% | 2,875 | $80K | |
| 82150 | <1% | 1,563 | $78K | |
| 82607 | <1% | 3,033 | $75K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 200 | $73K |
| 86140 | <1% | 2,590 | $72K | |
| 87507 | <1% | 307 | $72K | |
| 97597 | <1% | 3,166 | $71K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,393 | $71K |
| 93971 | <1% | 1,090 | $67K | |
| 86850 | <1% | 2,553 | $64K | |
| 87186 | <1% | 3,766 | $64K | |
| 76536 | <1% | 831 | $61K | |
| 74022 | <1% | 1,383 | $60K | |
| 85652 | <1% | 2,662 | $59K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,064 | $59K |
| 73610 | <1% | 1,686 | $58K | |
| 85045 | <1% | 4,133 | $56K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,688 | $55K |
| 73030 | <1% | 1,862 | $55K | |
| 72110 | <1% | 1,122 | $54K | |
| 73130 | <1% | 1,608 | $53K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,921 | $53K |
| 82728 | <1% | 1,827 | $53K | |
| 86900 | <1% | 2,639 | $51K | |
| 86901 | <1% | 2,643 | $50K | |
| 82746 | <1% | 1,512 | $49K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 671 | $48K |
| 96367 | <1% | 482 | $47K | |
| 83540 | <1% | 2,042 | $45K | |
| 70486 | <1% | 446 | $45K | |
| 85027 | <1% | 3,986 | $44K | |
| 97161 | <1% | 806 | $43K | |
| 87522 | Neg quan hep c or qual rna | <1% | 495 | $42K |
| 83550 | <1% | 1,083 | $39K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 93 | $38K |
| 83615 | <1% | 4,432 | $38K | |
| 80076 | <1% | 1,311 | $37K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 775 | $37K |
| 73110 | <1% | 1,012 | $36K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 1,099 | $35K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,219 | $35K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 233 | $33K |
| 93880 | <1% | 108 | $33K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 699 | $30K |
| 84702 | <1% | 1,093 | $30K | |
| 85378 | <1% | 1,175 | $30K | |
| 74018 | <1% | 918 | $29K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 77 | $29K |
| 59025 | Fetal non-stress test | <1% | 1,294 | $28K |
| 88312 | <1% | 244 | $28K | |
| 51702 | <1% | 556 | $28K | |
| 76830 | Ultrasound, transvaginal | <1% | 355 | $28K |
| 82140 | <1% | 1,449 | $27K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 588 | $27K |
| 99218 | <1% | 804 | $27K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,990 | $27K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 705 | $26K |
| 80164 | <1% | 44 | $25K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 789 | $25K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,283 | $24K |
| 72131 | <1% | 284 | $24K | |
| 74019 | <1% | 480 | $24K | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 307 | $23K |
| 94060 | <1% | 474 | $23K | |
| 73564 | <1% | 475 | $23K | |
| 80050 | General health panel | <1% | 638 | $23K |
| 73502 | <1% | 863 | $22K | |
| 82248 | <1% | 1,712 | $22K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,089 | $22K |
| 87902 | <1% | 27 | $21K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 671 | $21K |
| 64483 | <1% | 23 | $20K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,192 | $20K |
| 82565 | <1% | 911 | $20K | |
| 76770 | <1% | 343 | $20K | |
| 86780 | <1% | 746 | $19K | |
| 90715 | <1% | 323 | $19K | |
| 84520 | <1% | 860 | $19K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 234 | $18K |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 527 | $18K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 318 | $18K |
| 84481 | <1% | 849 | $18K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 55 | $17K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 991 | $16K |
| 94729 | <1% | 320 | $16K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,092 | $15K |
| 77065 | Tomosynthesis, mammo | <1% | 118 | $15K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 37 | $15K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 648 | $15K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 837 | $14K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 661 | $14K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 204 | $14K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 61 | $13K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 631 | $13K |
| 52000 | <1% | 41 | $13K | |
| 82009 | <1% | 546 | $13K | |
| 72050 | <1% | 254 | $13K | |
| 72100 | <1% | 398 | $13K | |
| 94726 | <1% | 339 | $13K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 106 | $13K |
| 82270 | <1% | 446 | $12K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 195 | $12K |
| 86063 | <1% | 336 | $12K | |
| 87075 | <1% | 582 | $12K | |
| 11045 | <1% | 252 | $12K | |
| 82784 | <1% | 76 | $12K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 582 | $12K |
| 88304 | <1% | 265 | $12K | |
| 83516 | <1% | 509 | $11K | |
| 73590 | <1% | 252 | $11K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 661 | $11K |
| 99152 | <1% | 56 | $11K | |
| 73090 | <1% | 229 | $11K | |
| 73080 | <1% | 357 | $10K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 204 | $10K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 310 | $10K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 210 | $9K |
| 72072 | <1% | 161 | $9K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 192 | $9K |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 33 | $9K |
| 96368 | <1% | 268 | $9K | |
| 86038 | <1% | 520 | $8K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 118 | $8K |
| 86706 | <1% | 412 | $8K | |
| 93970 | <1% | 135 | $8K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 155 | $7K |
| 89220 | <1% | 20 | $7K | |
| 88104 | <1% | 31 | $6K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 52 | $6K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 13 | $6K |
| 70491 | <1% | 41 | $6K | |
| 87205 | <1% | 178 | $6K | |
| 77066 | Tomosynthesis, mammo | <1% | 58 | $6K |
| 76642 | <1% | 127 | $5K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 44 | $5K |
| 84550 | <1% | 432 | $5K | |
| 86803 | <1% | 232 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 206 | $5K |
| 31500 | <1% | 76 | $5K | |
| 88311 | <1% | 25 | $4K | |
| 12001 | <1% | 52 | $4K | |
| 12002 | <1% | 35 | $4K | |
| 10060 | <1% | 47 | $4K | |
| 87340 | <1% | 193 | $4K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 232 | $4K |
| 93925 | <1% | 29 | $4K | |
| 97164 | <1% | 111 | $4K | |
| 93922 | <1% | 39 | $3K | |
| 11043 | <1% | 23 | $3K | |
| 82397 | <1% | 647 | $3K | |
| 71101 | <1% | 32 | $3K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 107 | $2K |
| 87320 | <1% | 137 | $2K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 98 | $2K |
| 82103 | <1% | 103 | $2K | |
| 83970 | <1% | 57 | $2K | |
| 86308 | <1% | 106 | $2K | |
| 70496 | <1% | 29 | $2K | |
| 72170 | <1% | 55 | $2K | |
| 36430 | <1% | 14 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 50 | $2K |
| 82043 | <1% | 172 | $2K | |
| 72128 | <1% | 15 | $2K | |
| 84153 | <1% | 74 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 12 | $1K |
| 86762 | <1% | 110 | $1K | |
| 72040 | <1% | 14 | $1K | |
| 77080 | <1% | 14 | $1K | |
| 0002A | <1% | 88 | $1K | |
| 83655 | <1% | 74 | $1K | |
| 70498 | <1% | 15 | $1K | |
| 73552 | <1% | 33 | $998.17 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 18 | $963.40 |
| 86677 | <1% | 54 | $934.35 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 16 | $933.81 |
| 0001A | <1% | 82 | $914.32 | |
| 87420 | <1% | 20 | $907.72 | |
| 86787 | <1% | 63 | $885.29 | |
| 87449 | <1% | 68 | $880.62 | |
| 87081 | <1% | 65 | $803.81 | |
| 86430 | <1% | 104 | $788.51 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 23 | $783.88 |
| 85018 | <1% | 86 | $763.04 | |
| 84156 | <1% | 65 | $760.95 | |
| 82247 | <1% | 78 | $727.19 | |
| 83010 | <1% | 39 | $700.59 | |
| Q3014 | Telehealth originating site facility fee | <1% | 50 | $647.44 |
| A9270 | Non-covered item or service | <1% | 108 | $616.58 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 13 | $612.27 |
| 76870 | <1% | 14 | $595.26 | |
| 83525 | <1% | 53 | $577.37 | |
| 82378 | <1% | 30 | $443.83 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 20 | $404.00 |
| 43753 | <1% | 12 | $392.00 | |
| C1769 | Guide wire | <1% | 55 | $389.00 |
| 88300 | <1% | 15 | $368.03 | |
| 83883 | <1% | 40 | $366.36 | |
| 97116 | <1% | 31 | $356.17 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 12 | $310.03 |
| 84436 | <1% | 49 | $256.24 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 24 | $251.91 |
| 84460 | <1% | 26 | $226.78 | |
| 86922 | <1% | 16 | $223.59 | |
| 82950 | <1% | 17 | $212.10 | |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 51 | $194.94 |
| 86735 | <1% | 13 | $154.05 | |
| 86765 | <1% | 13 | $151.96 | |
| 82172 | <1% | 13 | $151.84 | |
| 82977 | <1% | 27 | $131.68 | |
| 82542 | <1% | 16 | $130.08 | |
| 82465 | <1% | 36 | $114.35 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 30 | $75.23 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 20 | $69.25 |
| 82947 | <1% | 14 | $38.94 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 15 | $1.47 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTRAYLOR, JOHNETTA (AO)
| Provider | Location | Paid |
|---|---|---|
| Phc-Cleveland LLC | Cleveland, MS | $23.43M |
| Hartsville, LLC | Hartsville, SC | $18.42M |
| Logan Memorial Hospital LLC | Russellville, KY | $14.29M |
| Southwestern Medical Center, LLC | Lawton, OK | $9.40M |
| Palestine Principal Healthcare Limited Partnership | Palestine, TX | $6.80M |
| Watertown Medical Center LLC | Watertown, WI | $6.31M |
| Amg - Livingston, LLC | Livingston, TN | $5.52M |
| Logan General Hospital LLC | Logan, WV | $4.91M |
| ST. Joseph Hospital LLC | Lewiston, ID | $4.67M |
| Riverton Memorial Hospital LLC | Riverton, WY | $4.65M |
| Livingston Regional Hospital LLC | Livingston, TN | $4.33M |
| Hartsville Medical Group LLC | Hartsville, SC | $4.16M |
| Mexia Principal Healthcare Limited Partnership | Mexia, TX | $2.19M |
| Palestine Principal Healthcare Limited Partnership | Palestine, TX | $1.27M |
| Texas Specialty Physicians | Palestine, TX | $1.26M |
| ST Joseph Hospital LLC | Lewiston, ID | $1.10M |
| Watertown Physician Practices LLC | Watertown, WI | $244K |
| Watertown Physician Practices LLC | Watertown, WI | $175K |
| Amg-Livingston LLC | Livingston, TN | $165K |
| Watertown Physician Practices LLC | Watertown, WI | $149K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.